← Back to Clinical Trials
Recruiting NCT06425029

NCT06425029 Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06425029
Status Recruiting
Phase
Sponsor Dartmouth-Hitchcock Medical Center
Condition Epilepsy
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2025-07-22
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Experimental Intervention (Music A)Active Comparator Intervention (Music B)Active Comparator Intervention (Music C)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 24 participants in total. It began in 2025-07-22 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective, placebo-controlled, double-blinded randomized study of self-administered auditory intervention in a naturalistic home environment.

Eligibility Criteria

Inclusion Criteria: * Adults with medication-refractory focal epilepsy who have undergone RNS implantation at least six months prior and are in the judgement of the treating physician on a stable RNS regimen in terms of stimulation * Willing to attend all study visits and complete all required study procedures * Access to private or public wireless data service at regular intervals * Access to personal mobile device Exclusion Criteria: * Documentation of a musicogenic, or auditory-triggered focal seizure semiology * Participant is unable to reasonably participate in study tasks as determined by the investigator * Inability to obtain informed consent from the patient or legally authorized representative

Contact & Investigator

Central Contact

Anastasia Kanishcheva, MPH

✉ Anastasia.Kanishcheva@Hitchcock.ORG

📞 603-650-0260

Principal Investigator

Brian C Fidali, MD

PRINCIPAL INVESTIGATOR

Dartmouth-Hitchcock Medical Center

Frequently Asked Questions

Who can join the NCT06425029 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06425029 currently recruiting?

Yes, NCT06425029 is actively recruiting participants. Contact the research team at Anastasia.Kanishcheva@Hitchcock.ORG for enrollment information.

Where is the NCT06425029 trial being conducted?

This trial is being conducted at Worcester, United States, Lebanon, United States.

Who is sponsoring the NCT06425029 clinical trial?

NCT06425029 is sponsored by Dartmouth-Hitchcock Medical Center. The principal investigator is Brian C Fidali, MD at Dartmouth-Hitchcock Medical Center. The trial plans to enroll 24 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology